Niqin Xiao

Dr. Niqin Xiao

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
NXNiqin Xiao
Niqin Xiao
ZXZhaohu Xie
Zhaohu Xie
ZHZhiyan He
Zhiyan He
YXYundong Xu
Yundong Xu
SZShuyu Zheng
Shuyu Zheng
ZLZhao Fu Li
Zhao Fu Li

29 January 2025 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
YXYujiang Xi
Yujiang Xi
ZWZhifeng Wang
Zhifeng Wang
YWYuanyuan Wei
Yuanyuan Wei
NXNiqin Xiao
Niqin Xiao
LDLi Duan
Li Duan
DQDongdong Qin
Dongdong Qin

Verified
Journal Article
Open access
PDF file
JZJian Zhang
Jian Zhang
BCBingbing Chen
Bingbing Chen
QYQianqian Yang
Qianqian Yang
HYHeguo Yan
Heguo Yan
NXNiqin Xiao
Niqin Xiao
ZLZhaofu Li
Zhaofu Li
Osteoporosis (OP) and osteoarthritis (OA) are two common degenerative musculoskeletal disorders associated with aging and are traditionally classified and managed as distinct disease entities. Emerging evidence suggests that OP and OA may share bidirectional associations and common biological mechanisms, and that under specific pathological conditions they may develop into a mutually reinforcing comorbid state. The comorbidity of osteoporosis and osteoarthritis (OP–OA) is not a simple superimposition of bone loss and cartilage degeneration; rather, it represents a disorder of the osteochondral unit centered on disruption of the subchondral bone microenvironment. Alterations in the structural strength, remodeling dynamics, vascular and neural status, and bone marrow lesions of subchondral bone collectively reshape the local microenvironment, thereby directly affecting mechanical signal transmission and cellular behavior within the joint. Focusing on the subchondral bone microenvironment as the central pathological nexus, this review systematically summarizes how mechanical imbalance, aberrant bone remodeling, inflammatory activation, metabolic dysregulation, and cellular senescence jointly remodel the local niche in OP–OA comorbidity. These microenvironmental changes further induce phenotypic remodeling and fate deviation of bone marrow mesenchymal stem cells, bone remodeling-related cells, osteoimmune cells, and chondrocytes. On this basis, we integrate the regulatory roles of developmental signaling, mechanotransduction pathways, and inflammatory–immune signaling networks, and propose that microenvironment-driven cell fate plasticity may serve as a key mechanistic hub promoting the initiation and progression of OP–OA comorbidity as well as the persistent destabilization of the osteochondral unit. This perspective may help overcome the limitations of current studies that address OP and OA separately, and may provide a theoretical framework for early identification and stratification, biomarker discovery, and combined precision-targeted interventions for this comorbid condition.

9 February 2026 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
LSLihe Sheng
Lihe Sheng
NXNiqin Xiao
Niqin Xiao
BCBingbing Chen
Bingbing Chen
YXYang Xiang
Yang Xiang
ZXZhaohu Xie
Zhaohu Xie
ZLZhao Fu Li
Zhao Fu Li

15 April 2025 in Biomedical Chromatography
Verified
Journal Article
Closed access
YXYundong Xu
Yundong Xu
XZXiaoyu Zhang
Xiaoyu Zhang
NXNiqin Xiao
Niqin Xiao
QYQianqian Yang
Qianqian Yang
HYHeguo Yan
Heguo Yan
ZLZhao Fu Li
Zhao Fu Li

22 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
NXNiqin Xiao
Niqin Xiao
HYHeguo Yan
Heguo Yan
YXYujiang Xi
Yujiang Xi
YXYundong Xu
Yundong Xu
JZJian Zhang
Jian Zhang
ZXZhao hu Xie
Zhao hu Xie
Rheumatoid arthritis (RA) is an autoimmune disease primarily characterized by chronic, erosive polyarthritis. It is associated with a high rate of disability, and its pathogenesis remains incompletely understood. Uncontrolled chronic inflammation, synovial hyperplasia, Pannus formation, and bone destruction in RA patients remain the core challenges facing current clinical treatment, and the inflammatory response is generally considered the initiating factor for this series of pathological processes. In an inflammatory environment, the body’s metabolic rate accelerates, leading to increased local oxygen consumption and ultimately creating a hypoxic microenvironment. Research has shown that under hypoxic conditions, glycolysis serves as the body’s primary energy pathway and is essential for sustaining the inflammatory response. Furthermore, lactate, a byproduct of glycolysis, functions not only as a metabolic byproduct but also as a precursor molecule; through lactylation, it contributes to the progression of RA. Although this metabolic–epigenetic axis is a common feature of various chronic inflammatory diseases, its effects on joint pathology may contribute to RA progression. Therefore, this article focuses on the intrinsic connections among hypoxia, glycolysis, and lactylation, and systematically reviews the immunological and inflammatory mechanisms of glycolysis in RA, the relationship between glycolysis and synovial hyperplasia, Pannus formation, and bone destruction in RA, and the role of lactate modification in promoting the pathological progression of RA. It also summarizes the latest research advances in RA therapies targeting hypoxia, glycolysis, and lactate modification, aiming to provide a theoretical basis for a deeper understanding of the pathogenesis of RA and the development of targeted treatment strategies.